Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England.

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

Informations de copyright

© 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

Farah Toron and Paula Williams are employees of Bristol Myers Squibb. Emma Tyas is an employee of Lumanity, which received fees from Bristol Meyers Squibb in relation to this study. Miranda Cooper and Joshua Rickards were employees of Lumanity at the time of this study. Christopher P. Fox has received remuneration for consultancy and/or participation in advisory boards from Abbvie, AstraZeneca, Atarabio, BMS/Celgene, GenMab, Gilead/Kite, Incyte, Janssen, Lilly, Morphosys, Ono, Roche, SERB, SOBI, and Takeda. Christopher P. Fox also received research funding from BeiGene. William Townsend has received remuneration for consulting from Roche and Gilead and has received remuneration for speaking at educational events from Roche, and for participating in advisory boards from BMS and Takeda. John G. Gribben has received honoraria from Abbvie, Amgen, AstraZeneca, BMS, Gilead/Kite, and Janssen. John G. Gribben also received gratin fusing from AstraZeneca, Celgene, and Janssen. Tobias Menne has received travel grants from Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, BMS/Celgene, Gilead/Kite, Janssen, and Takeda and also received honoraria for advisory board meetings from Gilead/Kite, Amgen, Novartis, Pfizer, BMS/Celgene, Daiichi Sankyo, Atara, Roche, and Janssen. Tobias Menne has received honoraria for lectures from Gilead/Kite, Takeda, Janssen, Roche, Servier, Novartis, BMS/Celgene, Pfizer, and Incyte, and received research funding from Janssen, AstraZeneca, and Novartis Nagesh Kalakonda received remuneration for lectures. presentations, manuscript writing, and/or educational events from BMS/Celgene, Takeda, Morphosys, Incyte, Janssen, Karyopharm, Roche, and Gilead, and received support for attending meetings from Janssen, Morphosys, and Takeda. John Radford has received remuneration for consultancy from Takeda and ADC Therapeutics. JR's spouse is a shareholder in AstraZeneca.